Compounds > milrinone

milrinone and sulfinpyrazone

milrinone has been researched along with sulfinpyrazone in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (85.71)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Cano, E; Coelho, A; Crespo, A; Fraiz, N; Laguna, R; Lemière, GL; Maes, BU; Meyers, C; Raviña, E; Sotelo, E; Yáñez, M1
Cano, E; Coelho, A; Fraiz, N; Laguna, R; Raviña, E; Sotelo, E; Yáñez, M1
Cano, E; Coelho, A; Elmaatougi, A; Fraiz, N; García-Mera, X; Laguna, R; Lemière, GL; Maes, BU; Meyers, C; Sotelo, E; Verhelst, T; Yáñez, M1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1

Other Studies

7 other study(ies) available for milrinone and sulfinpyrazone

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.
    Bioorganic & medicinal chemistry letters, 2006, Feb-15, Volume: 16, Issue:4

    Topics: Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridazines; Stereoisomerism; Structure-Activity Relationship

2006
Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.
    Journal of medicinal chemistry, 2007, Dec-27, Volume: 50, Issue:26

    Topics: Alkenes; Blood Platelets; Drug Design; Humans; In Vitro Techniques; Platelet Aggregation Inhibitors; Pyridazines; Stereoisomerism; Structure-Activity Relationship

2007
2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.
    Bioorganic & medicinal chemistry letters, 2008, Jan-15, Volume: 18, Issue:2

    Topics: Drug Design; Platelet Aggregation Inhibitors; Pyridazines; Structure-Activity Relationship

2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010